As TNFα and IL-1β inhibitors are now available to treat severe ICB induced immune related adverse events (54), it is encouraging that blocking these pathways did not diminish the anti-tumor responses of chemo-immunotherapy in preclinical models. This evidence concerns the gene IL1B and neoplasm.